FDA drug approval, importation. Monitoring of changes to prescription drug advertising. PBM reform proposals, NIH funding, support and clinical trials.
2026 · 2nd Quarter (Apr 1 - June 30)
CALIFORNIA LIFE SCIENCES
Filed by WILLIAMS AND JENSEN, PLLC.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 20, 2026
- Income
- $20,000.00
- Expenses
- Not reported
- Registrant
- WILLIAMS AND JENSEN, PLLC
- Client
- CALIFORNIA LIFE SCIENCES
- Filing UUID
- f32f61c0-91b7-495f-9570-73a3f5c52cdf
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
H.R. 1, One Big Beautiful Bill Act, issues related to R&D tax credit. Monitor trade and tariff issues related to pharmaceutical tariffs. Health care IP.
Literal federal measure citations: H.R. 1
H.R. 1, One Big Beautiful Bill Act implementation of ORPHAN CURES Act, Transitional coverage for innovative medical devices (Ensuring Patient Access to Critical Breakthrough Products Act), IRA implementation of drug pricing provisions, Oppose proposed changes to the Medicaid Drug Rebate Program, Medicare coverage for anti-obesity medication and multi-cancer screening tests.
Literal federal measure citations: H.R. 1
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.